CORRELATION OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT PRO BNP) WITH SERUM FERRITIN AND NUMBER OF BLOOD TRANSFUSIONS IN THALASSEMIA PATIENTS-A CROSS-SECTIONAL STUDY

APARNA DUTT; MALLESH KARIYAPPA; RAVICHANDRA KOTHUR RANGEGOWDA

doi:10.22159/ijcpr.2023v15i5.3070

Authors

APARNA DUTT Department of Paediatrics, Bangalore Medical College and Research Institute, Bangalore-560002, Karnataka, India
MALLESH KARIYAPPA Department of Paediatrics, Bangalore Medical College and Research Institute, Bangalore-560002, Karnataka, India
RAVICHANDRA KOTHUR RANGEGOWDA Department of Paediatrics, Bangalore Medical College and Research Institute, Bangalore-560002, Karnataka, India

DOI:

https://doi.org/10.22159/ijcpr.2023v15i5.3070

Keywords:

Biochemical marker, Chelation, Genetics, Heart failure

Abstract

Objective: Thalassemia is a genetic disorder of globin chain production in which there is an imbalance between alpha globin and beta globin chain production. Thalassemia patients require frequent blood transfusions to maintain adequate tissue oxygenation, which can cause a state of iron overload. NT pro BNP is a sensitive biomarker to detect cardiac iron overload. Our objective of this study was to estimate the level of NTproBNP in beta-thalassemia patients and to find out the correlation of NT pro BNP with serum ferritin levels and the number of blood transfusions.
Methods: 50 thalassemic patients aged below 18 y with no known cardiac comorbidities were enrolled in this cross-sectional study. The correlation between the levels of NT-pro BNP with serum ferritin and number of blood transfusions and chelation therapy was measured.
Results: This study demonstrated that the levels of NT Pro BNP were elevated in thalassemia patients with a positive correlation with serum ferritin values and the number of blood transfusions which the patients received.
Conclusion: This Study also concluded that NT Pro BNP can be used as a biochemical marker used to detect early stages of cardiac failure and also to identify patients going for heart failure, especially in resource-limited settings.

Downloads

Download data is not yet available.

References

DeBaun RM, Feri Jones JM, Vichinsky P. Hemoglobinopathies. In: Nelson textbook of paediatrics.20th ed. Vol. 2. Amsterdam: Elsevier; 2016. p. 2349.

Madan N, Sharma S, Sood SK, Colah R, Bhatia LH. Frequency of β-thalassemia trait and other hemoglobinopathies in northern and western India. Indian J Hum Genet. 2010;16(1):16-25. doi: 10.4103/0971-6866.64941, PMID 20838487.

Balgir R. Genetic heterogeneity of population structure in 15 major scheduled tribes in central-eastern India: a study of immuno-hematological disorders. Indian J Hum Genet. 2006;12(2):86. doi: 10.4103/0971-6866.27792.

Hershko C. Iron loading and its clinical implications. Am J Hematol. 2007;82(12) Suppl:1147-8. doi: 10.1002/ajh.21070, PMID 17963253.

Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol. 1990;84(3):113-7. doi: 10.1159/000205046, PMID 2123060.

Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, Gozzard DI. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res. 1980;14(12):719-24. doi: 10.1093/cvr/14.12.719, PMID 7260965.

Spirito P, Lupi G, Melevendi C, Vecchio C. Restrictive diastolic abnormalities identified by doppler echocardiography in patients with thalassemia major. Circulation. 1990;82(1):88-94. doi: 10.1161/01.cir.82.1.88, PMID 2364528.

Kremastinos DT, Tsiapras DP, Kostopoulou AG, Hamodraka ES, Chaidaroglou AS, Kapsali ED. NT-proBNP levels and diastolic dysfunction in beta-thalassaemia major patients. Eur J Heart Fail. 2007;9(5):531-6. doi: 10.1016/j.ejheart.2006.11.004, PMID 17317307.

Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26(21):2277-84. doi: 10.1093/eurheartj/ehi406, PMID 16014646.

Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-9. doi: 10.1053/euhj.2001.2822, PMID 11913479.

Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV. On T2* magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519-28. doi: 10.1161/circulationaha.110.007641, PMID 21444881.

Leonardi B, Margossian R, Colan SD, Powell AJ. Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia. JACC Cardiovasc Imaging. 2008;1(5):572-8. doi: 10.1016/j.jcmg.2008.04.005, PMID 19356483.

Vlachou M, Kamperidis V, Giannakoulas G, Karamitsos T, Vlachaki E, Karvounis H. Biochemical and imaging markers in patients with thalassaemia. Hellenic J Cardiol. 2021;62(1):4-12. doi: 10.1016/j.hjc.2020.04.012, PMID 32387594.

Hahalis G, Kourakli A, Gerasimidou I, Kalogeropoulos AP, Sitafidis G, Papageorgiou U. Cardiac mortality in β-thalassemia major: resting but not dobutamine stress echocardiography predicts mortality among initially cardiac disease-free patients in a prospective 12 y study. Eur J Heart Fail. 2009;11(12):1178-81. doi: 10.1093/eurjhf/hfp152, PMID 19889689.

Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574-8. doi: 10.1056/NEJM199409013310903, PMID 8047081.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehw128, PMID 27206819.

Kremastinos DT, Hamodraka E, Parissis J, Tsiapras D, Dima K, Maisel A. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major. Am Heart J. 2010;159:68–74

Balkan C, Tuluce SY, Basol G, Tuluce K, Ay Y, Karapinar DY. Relation between NT-proBNP levels, iron overload, and early stage of myocardial dysfunction in β-thalassemia major patients. Echocardiography. 2012 Mar;29(3):318-25. doi: 10.1111/j.1540-8175.2011.01584.x, PMID 22066516.

Noori NM, Teimouri A, Nakhaey Moghaddam M. Diagnostic value of NT-pro BNP biomarker and echocardiography in cardiac involvements in beta-thalassemia patients. Int J Pediatr. 2017;5(11):6077-94.

Alizadeh B, Badiee Z, Mahmoudi M, Mohajery M. Evaluating the correlation between serum NT-proBNP level and diastolic dysfunction severity in beta-thalassemia major patients. J Tehran Heart Cent. 2016;11(2):68-72. PMID 27928257.

Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart. 2003;89(7):745-51. doi: 10.1136/heart.89.7.745, PMID 12807847.

Mehrzad V, Khajouei AS, Fahami E. Correlation of N-terminal pro-B-type natriuretic peptide levels and cardiac magnetic resonance imaging T2* in patients with β-thalassaemia major. Blood Transfus. 2016;14(6):516-20. doi: 10.2450/2016.0120-15, PMID 27136436.